CIK 0001750149 · Non-accelerated filer<br>Smaller reporting company
Inhibikase Therapeutics, Inc.
Sign in to watch- Ticker
- IKT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 263407249
- Phone
- (302) 295-3800
- Business address
- 1000 N. WEST STREET, SUITE 1200, WILMINGTON, DE, 19801
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-19 | Wasserman Scott M. Director | Grant or award · Stock Option (Right to Buy) | +310,000 | 310,000 | ||
| 2026-07-30 | BERMAN DENNIS N Director | Option exercise | +21,854 | $1.26 | $28K | 21,854 |
| 2026-07-30 | BERMAN DENNIS N Director | Option exercise · Stock Option (Right to Buy) | −21,854 | 0 | ||
| 2026-07-29 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Other disposition | −18,030,000 | 6,970,000 | ||
| 2026-07-29 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Other acquisition · Pre-Funded Warrant (Right to Buy) | +18,030,000 | 18,030,000 | ||
| 2026-06-26 | BERMAN DENNIS N Director | Grant or award · Stock Option (Right to Buy) | +155,000 | 155,000 | ||
| 2026-06-26 | Canner David Director | Grant or award · Stock Option (Right to Buy) | +155,000 | 155,000 | ||
| 2026-06-26 | Kush Arvind Director | Grant or award · Stock Option (Right to Buy) | +155,000 | 155,000 | ||
| 2026-06-26 | Bellini Roberto Director | Grant or award · Stock Option (Right to Buy) | +155,000 | 155,000 | ||
| 2026-06-26 | Aurentz Vincent Director | Grant or award · Stock Option (Right to Buy) | +155,000 | 155,000 | ||
| 2026-06-26 | Munshi Amit Director | Grant or award · Stock Option (Right to Buy) | +155,000 | 155,000 | ||
| 2026-02-21 | Aurentz Vincent Director | Returned to the company | −255,299 | 510,596 | ||
| 2026-02-21 | Cabell Christopher President & Head of R&D | Returned to the company | −338,282 | 676,564 | ||
| 2026-02-21 | Munshi Amit Director | Returned to the company | −19,089 | 38,176 | ||
| 2026-01-05 | Iwicki Mark T Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +4,982,706 | 4,982,706 | ||
| 2026-01-05 | Cabell Christopher President & Head of R&D | Grant or award · Stock Option (Right to Buy) | +900,117 | 900,117 | ||
| 2026-01-05 | McIntyre David Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +986,319 | 986,319 | ||
| 2025-11-21 | Sands Capital Life Sciences Pulse Fund II, L.P. 10% owner | Purchase | +2,068,965 | $1.45 | $3.0M | 13,018,965 |
| 2025-06-30 | Aurentz Vincent Director | Grant or award · Stock Option (Right to Buy) | +108,176 | 108,176 | ||
| 2025-06-30 | Canner David Director | Grant or award · Stock Option (Right to Buy) | +108,176 | 108,176 |
Page 1 of 9 · 163 trades